β-Carbolines are a large family of indole alkaloids found both outside the body (in cooked foods, tobacco smoke, coffee, and alcoholic drinks) and inside it (measurable in blood and, in some contexts, brain-related tissues).

Their reputation is mixed: some members and metabolites have been studied as neurotoxins, while others show neuroprotective, anti-inflammatory, or neuromodulatory effects in cells and animals (Gruss et al. 2012).

That dual identity matters for any “cognitive enhancement” narrative. The same chemical scaffold can interact with multiple brain targets—sometimes in opposite directions depending on dose, substitution pattern, and metabolic context.

The most discussed β-carbolines in neuropharmacology include harmine, harmaline, harman (harmane), norharman, and the research compound 9-methyl-β-carboline (9-Me-BC).

MAO-A inhibition

A central mechanism is inhibition of monoamine oxidase A (MAO-A), an enzyme that breaks down monoamines such as serotonin and norepinephrine (and, indirectly, can shape dopamine signaling).

In an in-vitro study of purified enzyme, harmine and harmaline were among the most potent MAO-A inhibitors tested, with Ki values in the tens of nanomolar range (harmine 5 nM, harmaline 48 nM, reported alongside other β-carbolinium compounds) (Kim et al. 1997).

MAO-A inhibition is a double-edged sword for cognitive enhancement. Raising monoamine tone can plausibly influence motivation, attention, and mood, but MAO inhibition is also the reason β-carbolines carry interaction risks (for example, with serotonergic drugs) and can produce nausea, blood-pressure effects, and other adverse events at higher exposures—points now supported by modern controlled human dosing with purified harmine (Ables et al. 2024).

Beyond MAO-A, different β-carbolines have been reported to touch cholinergic enzymes (e.g., acetylcholinesterase), inflammatory signalling, and growth-factor pathways in preclinical models—mechanisms that, at least on paper, overlap with popular “cognitive enhancement” themes such as synaptic plasticity and neurotrophic support.

The Clinical Evidence

Human evidence that cleanly isolates β-carbolines from other psychoactive ingredients is still limited—but it is improving. Most clinical discussion comes from two contexts:

1. Ayahuasca studies, where β-carbolines (notably harmine/harmaline/tetrahydroharmine) act alongside DMT.
2. Purified harmine dosing studies, which directly test a single β-carboline in humans.

The most-cited controlled clinical result is a randomized, double-blind, placebo-controlled trial in treatment-resistant depression (n = 29) reporting rapid antidepressant effects after a single dosing session (Palhano-Fontes et al. 2019).

Depression scores (MADRS) favoured ayahuasca over placebo at multiple time points, with between-group effect sizes (Cohen’s d) of 0.84 at day 1 and day 2, rising to 1.49 at day 7. The day-7 response rate was 64% with ayahuasca vs 27% with placebo (p = 0.04), and remission showed a trend (36% vs 7%, p = 0.054) (Palhano-Fontes et al. 2019).

From a nootropic perspective, mood matters because motivation and cognitive performance often improve when depression lifts—but that is not the same as a direct cognitive enhancer effect. Still, the same research group and collaborators have probed biomarkers linked to neuroplasticity.

In a related randomized design examining serum brain-derived neurotrophic factor (BDNF), participants treated with ayahuasca showed higher BDNF 48h post-dose than placebo (GLM F = 4.81, p = 0.03; Cohen’s d = 0.53).

The paper reports baseline subgroup means such as 10,229.54 ± 506.92 pg/mL BDNF in a hypocortisolemic subgroup vs 12,574.61 ± 680.59 pg/mL in eucortisolemic participants (p = 0.016), and it finds a negative correlation between BDNF and depression severity at day 2 in ayahuasca-treated patients (Spearman rho = −0.55) (Almeida et al. 2019).

These results are clinically interesting, but they still do not prove that β-carbolines are purely cognitive enhancing—because ayahuasca combines β-carbolines with DMT and a powerful acute subjective experience that can alter sleep, stress hormones, and behaviour for days.

Harmine

A key step forward is a modern Phase 1 single-ascending-dose study of pharmaceutical-grade oral harmine HCl in healthy volunteers (Ables et al. 2024). Here the main story is not cognitive enhancement—it’s what harmine does and does not do on its own:

• The authors conclude harmine can be orally administered at < 2.7 mg/kg with minimal or no adverse events (AEs), while doses > 2.7 mg/kg are associated with vomiting, drowsiness, and limited psychoactivity (Ables et al. 2024).
• In the detailed results, 2 of 10 participants at 100 mg reported AEs, both mild; and 2 of 15 (13%) participants had mild AEs at doses below 2.7 mg/kg. The paper emphasizes no dose-limiting toxicities below 2.7 mg/kg (Ables et al. 2024).
• The study reports no frank visual hallucinations at any dose, though a small number of participants at higher doses described mild perceptual changes (for example, “fuzzy outlines” or unusual somatic sensations). Cardiovascular measures were generally stable; one participant who vomited became transiently hypotensive (lowest BP 85/48) and received IV fluids (Ables et al. 2024).

For cognitive enhancement claims, this is sobering: pure harmine—at tolerable single doses—does not look like a robust standalone “smart drug” in humans. Its primary clinical signal so far is tolerability constraints and MAOI-like side effects rather than measurable cognitive gains.

Cognition And Neuroplasticity

In preclinical models, some β-carbolines improve performance on learning-and-memory tasks—often in impairment models (scopolamine, diabetes, toxin exposure), which is closer to “therapeutic rescue” than enhancement in healthy brains.

For example, in a scopolamine-induced cognitive impairment mouse model, harmaline and harmine were tested across multiple doses (harmaline 2, 5, 10 mg/kg; harmine 10, 20, 30 mg/kg) with n = 10 per group, alongside donepezil (5 mg/kg).

The study reports statistically significant modulation of cholinergic and inflammatory readouts (e.g., scopolamine increased acetylcholinesterase activity in cortex and hippocampus with F(8,81) = 10.553, p < 0.01 and F(8,81) = 6.177, p < 0.05, and multiple harmaline/harmine conditions reduced these measures) (Li et al. 2018).

In a diabetes-associated cognitive dysfunction rat model, harmine was given by oral gavage at 20 mg/kg for 12 weeks after STZ induction (diabetic threshold fasting glucose > 16.7 mmol/L). On Morris water maze measures, the paper reports significant group differences on later training days (e.g., distance day 3 p = 0.005, day 4 p = 0.005, day 5 p = 0.031; latency day 3 p = 0.034, day 4 p = 0.041, day 5 p = 0.034) and improved probe-trial metrics (platform crossings and target-quadrant time, n = 6 for those probe outcomes) (Liu et al. 2020).

These kinds of findings are consistent with a broad idea that some β-carbolines can support cognition when neural systems are perturbed by inflammation, metabolic stress, or cholinergic blockade. But translating them into claims about healthy-person enhancement is a leap.

9-Me-BC: Cognitive Enhancement & Dopaminergic Neurogenesis

No β-carboline has attracted more speculative “nootropic” attention online than 9-methyl-β-carboline (9-Me-BC). Importantly, 9-Me-BC is a research chemical without established clinical efficacy or safety for cognitive enhancement. The scientific interest comes from a cluster of preclinical results that are unusually dopamine-centered.

A rat study reported that 10 days (but not 5 days) of pharmacological treatment with 9-Me-BC improved performance on a hippocampus-dependent spatial task (radial maze), was associated with elevated dopamine levels in the hippocampal formation, and produced morphological signatures consistent with synaptic remodelling (more complex dendrites and higher spine counts in dentate gyrus granule neurons) (Gruss et al. 2012).

The strongest “dopaminergic regeneration” language comes from cell culture and Parkinson’s-relevant toxin models.

Cell culture: increased TH+ neurons and trophic signaling

• In primary dopaminergic cultures, 9-Me-BC increased the number of tyrosine hydroxylase–positive (TH+) neurons; one report quantified a 27 ± 7% increase after 70 μM 9-Me-BC exposure (Keller et al. 2020).
• The same paper reports that after 48 hours of 90 μM 9-Me-BC exposure in astrocyte cultures, gene expression of the neurotrophic factor artemin increased 3.2-fold (p < 0.01), while BDNF increased ~2-fold and several other plasticity-related genes rose modestly (e.g., Ncam1 ~1.4-fold, Ntf3 ~1.8-fold) (Keller et al. 2020).
• Mechanistically, they measured MAO inhibition directly, reporting IC50 ~1 μM for MAO-A and 15.5 μM for MAO-B (Keller et al. 2020).

These are real dopamine-system signals, but they do not necessarily equal neurogenesis in the adult brain. In cell culture, an increase in TH+ cells can reflect several non-exclusive possibilities: improved survival of existing dopaminergic neurons, phenotypic “recovery” of stressed neurons, differentiation of precursor cells present in the culture, or shifts in marker expression.

A pharmacological reports paper tested 9-Me-BC in a chronic MPP+ rat model designed to reduce striatal dopamine by about half. Key reported numbers include:

• The MPP+ regimen (0.284 mg/kg/day for 28 days) produced an ~50% reduction in dopamine in the infused (left) striatum. In the right striatum, dopamine remained in the sham range (reported as 5.1 ± 0.8 ng/mg, n = 6).
• After MPP+ infusion, rats received 9-Me-BC 0.105 mg/kg/day for 14 days (chosen as half the equimolar MPP+ dose). The paper states that dopamine levels on the affected side normalized with 9-Me-BC compared with MPP+ + saline (p < 0.01 vs the saline-followup group).
• In substantia nigra pars compacta stereology, MPP+ + saline rats showed fewer TH-immunoreactive cells on the left vs right (6,736 ± 238 vs 7,985 ± 464, p < 0.05, n = 8). With 9-Me-BC follow-up, TH-positive counts were closer to the right side (7,480 ± 478 vs 8,199 ± 498, n = 8), described as normalization.

This is the kind of dataset that fuels “regeneration” claims: dopamine content recovers, TH-positive cell counts rebound, and dopaminergic markers increase.

But even here, the most careful interpretation is functional and phenotypic restoration, not proven adult dopaminergic neurogenesis. The adult mammalian substantia nigra is not known for robust ongoing neuron production under normal conditions.

Showing true neurogenesis would require lineage tracing, birth-dating markers, and clear evidence that new neurons are generated and integrated—evidence not established by TH counts alone. The papers themselves acknowledge uncertainty about whether the apparent increase reflects differentiation, survival, or other mechanisms in earlier culture work.

Safety Concerns

The same body of literature repeatedly flags dose sensitivity. In one overview of 9-Me-BC work, exposure above certain concentrations was described as toxic in vitro (e.g., “higher concentrations were toxic”), and an older mouse experiment cited in the same review reported that systemic 9-Me-BC at 250 μmol/kg twice per day for 7 days decreased dopamine and serotonin in multiple brain regions (Wernicke et al. 2010).

This is the broader β-carboline theme again: small structural changes and dose changes can flip the story from stimulation and protection to impairment.

β-Carbolines are not “pro-cognitive” by default. Some are strongly associated with tremor and, at high exposure, with neurotoxicity narratives.

A classic case–control study of essential tremor measured blood β-carbolines in 100 cases and 100 controls, finding higher harmane in cases: mean log concentration 0.72 ± 0.53 vs 0.51 ± 0.64 g⁻¹⁰/mL (p = 0.01), with medians 5.21 vs 2.28 g⁻¹⁰/mL (p = 0.005). When stratified by the median, 62% of cases vs 39% of controls were in the “high harmane” group (p = 0.001) (Louis et al. 2002).

Even in behavioral pharmacology, not all β-carboline signals look “enhancing.” A rat intracranial self-stimulation study reported that harmane, norharmane, and harmine did not lower reward thresholds (a classic marker of reward-facilitation) and instead elevated thresholds, interpreted as aversive/anhedonic-like effects in that paradigm (Harris et al. 2020).

This matters for real-world nootropic hopes: any compound that nudges monoamines can also increase anxiety, disrupt sleep, blunt reward, or cause nausea—outcomes that can negate cognitive benefits.

β-carbolines as a nootropic

• Biochemically potent MAO-A inhibition at nanomolar K_i values for harmine/harmaline (Kim et al. 1997).
• Controlled human dosing of purified harmine demonstrating a relatively narrow tolerability window and mainly MAOI-like adverse effects rather than clear cognitive benefits (Ables et al. 2024).
• Clinical outcomes in ayahuasca trials that include large antidepressant effect sizes and measurable changes in neuroplasticity-linked biomarkers like BDNF—suggestive, but confounded by the multi-compound, high-intensity psychedelic context (Palhano-Fontes et al. 2019; Almeida et al. 2019).
• 9-Me-BC as a dopamine-plasticity probe, with animal data linking improved spatial learning to elevated hippocampal dopamine and dendritic/spine proliferation (Gruss et al. 2012), plus culture/toxin-model evidence consistent with restoration of dopaminergic function (Keller et al. 2020; Wernicke et al. 2010).

β-carbolines are best viewed as a pharmacological toolkit: a structurally related set of molecules that can push on monoamines, inflammation, and plasticity—sometimes in ways that might one day support cognition in defined clinical conditions. But they also carry built-in liabilities: tremorogenic potential, dose-sensitive toxicity, and MAOI interaction risk.

References

Ables, J. L., et al. (2024). A Phase 1 single ascending dose study of pure oral harmine in healthy volunteers. https://pmc.ncbi.nlm.nih.gov/articles/PMC11549898/

Almeida, R. N., et al. (2019). Modulation of Serum Brain-Derived Neurotrophic Factor by a Single Dose of Ayahuasca: Observation From a Randomized Controlled Trial. https://www.frontiersin.org/journals/psychology/articles/10.3389/fpsyg.2019.01234/full

Gruss, M., et al. (2012). 9-Methyl-β-carboline-induced cognitive enhancement is associated with elevated hippocampal dopamine levels and dendritic and synaptic proliferation. https://pubmed.ncbi.nlm.nih.gov/22380576/

Hamann, J., et al. (2008). 9-Methyl-beta-carboline up-regulates the appearance of differentiated dopaminergic neurones in primary mesencephalic culture. https://pubmed.ncbi.nlm.nih.gov/17913302/

Harris, A. C., et al. (2020). β-Carbolines found in cigarette smoke elevate intracranial self-stimulation thresholds in rats. https://pubmed.ncbi.nlm.nih.gov/32926882/

Kim, H., et al. (1997). Inhibition of monoamine oxidase A by beta-carboline derivatives. https://pubmed.ncbi.nlm.nih.gov/8990278/

Li, S. P., et al. (2018). Analogous β-Carboline Alkaloids Harmaline and Harmine Ameliorate Scopolamine-Induced Cognition Dysfunction by Attenuating Acetylcholinesterase Activity, Oxidative Stress, and Inflammation in Mice. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.00346/full

Liu, [Initials not shown in citation], et al. (2020). Harmine Ameliorates Cognitive Impairment by Inhibiting NLRP3 Inflammasome Activation and Enhancing the BDNF/TrkB Signaling Pathway in STZ-Induced Diabetic Rats. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.00535/full

Louis, E. D., et al. (2002). Elevation of blood β-carboline alkaloids in essential tremor. https://pubmed.ncbi.nlm.nih.gov/12499487/

Palhano-Fontes, F., et al. (2019). Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. https://pmc.ncbi.nlm.nih.gov/articles/PMC6378413/

Wernicke, C., et al. (2010). 9-Methyl-beta-carboline has restorative effects in an animal model of Parkinson’s disease. https://pubmed.ncbi.nlm.nih.gov/20360614/

Keller, S., et al. (2020). 9-Methyl-β-carboline inhibits monoamine oxidase activity and stimulates the expression of neurotrophic factors by astrocytes. https://pub.dzne.de/record/151649/files/DZNE-2020-01228.pdf